0000899243-23-020113.txt : 20231102 0000899243-23-020113.hdr.sgml : 20231102 20231102205043 ACCESSION NUMBER: 0000899243-23-020113 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20231031 FILED AS OF DATE: 20231102 DATE AS OF CHANGE: 20231102 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Fairey William CENTRAL INDEX KEY: 0001727275 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38130 FILM NUMBER: 231374207 MAIL ADDRESS: STREET 1: C/O CHEMOCENTRYX, INC. STREET 2: 850 MAUDE AVE. CITY: MOUNTAIN VIEW STATE: CA ZIP: 94043 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: AILERON THERAPEUTICS INC CENTRAL INDEX KEY: 0001420565 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-995-0900 MAIL ADDRESS: STREET 1: 738 MAIN STREET STREET 2: UNIT 398 CITY: WALTHAM STATE: MA ZIP: 02451 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2023-10-31 0 0001420565 AILERON THERAPEUTICS INC ALRN 0001727275 Fairey William C/O AILERON THERAPEUTICS, INC. 738 MAIN STREET #398 WALTHAM MA 02451 1 0 0 0 Stock Option (right to buy) 4.63 2031-11-16 Common Stock 17064 D On October 31, 2023, the Issuer completed its merger with Lung Therapeutics, Inc. (the "Merger") in accordance with the terms of the Agreement and Plan of Merger, dated October 31, 2023. In connection with the Merger, the Issuer assumed the Reporting Person's option to purchase 100,000 shares of Lung Therapeutics, Inc. common stock originally granted on November 17, 2021, which option was converted into an option to purchase 17,064 shares of Issuer common stock. The shares underlying the option vest annually on each anniversary of the grant date until the third anniversary of the grant date, subject to the Reporting Person's continued service with the Issuer on each applicable vesting date. Exhibit 24.1 Power of Attorney /s/ Manuel C. Alves-Aivado, M.D., Ph.D., as attorney-in-fact for William Fairey 2023-11-02 EX-24.1 2 attachment1.htm EX-24.1 DOCUMENT

       LIMITED POWER OF ATTORNEY FOR SECTION 16 REPORTING OBLIGATIONS

       Know all by these presents, that the undersigned hereby makes,
constitutes and appoints Manuel C. Alves Aivado, Susan L. Drexler, Brian
Windsor, Ph.D., and Charles Garner, signing singly and each acting individually,
as the undersigned's true and lawful attorney-in-fact with full power and
authority as hereinafter described to:

       (1)     execute for and on behalf of the undersigned, in the u
ndersigned's capacity as an officer of Aileron Therapeutics, Inc. (the
"Company"), Forms 3, 4, and 5 (including any amendments thereto) in accordance
with Section 16(a) of the Securities Exchange Act of 1934 and the rules
thereunder (the "Exchange Act");

       (2)     do and perform any and all acts for and on behalf of the
undersigned which may be necessary or desirable to prepare, complete and
execute any such Form 3, 4, or 5, prepare, complete and execute any amendment or
amendments thereto, and timely deliver and file such form with the United States
Securities and Exchange Commission (the "SEC") and any stock exchange or similar
authority, including without limitation the filing of a Form ID, Update
Passphrase, or any other application materials to enable the undersigned to gain
or maintain access to the Electronic Data Gathering, Analysis and Retrieval
system of the SEC;

       (3)     seek or obtain, as the undersigned's representative and on the
undersigned's behalf, information regarding transactions in the Company's
securities from any third party, including brokers, employee benefit plan
administrators and trustees, and the undersigned hereby authorizes any such
person to release any such information to such attorney-in-fact and approves and
ratifies any such release of information; and

       (4)     take any other action of any type whatsoever in connection with
the foregoing which, in the opinion of such attorney-in-fact, may be of benefit
to, in the best interest of, or legally required by, the undersigned, it being
understood that the documents executed by such attorney-in-fact on behalf of the
undersigned pursuant to this Power of Attorney shall be in such form and shall
contain such terms and conditions as such attorney-in-fact may approve in such
attorney-in-fact's discretion.

       The undersigned hereby grants to each such attorney-in-fact full power
and authority to do and perform any and every act and thing whatsoever
requisite, necessary, or proper to be done in the exercise of any of the rights
and powers herein granted, as fully to all intents and purposes as the
undersigned might or could do if personally present, with full power of
substitution or revocation, hereby ratifying and confirming all that such
attorney-in-fact, or such attorney-in-fact's substitute or substitutes, shall
lawfully do or cause to be done by virtue of this power of attorney and the
rights and powers herein granted.  The undersigned acknowledges that the
foregoing attorneys-in-fact, in serving in such capacity at the request of the
undersigned, are not assuming nor relieving, nor is the Company assuming nor
relieving, any of the undersigned's responsibilities to comply with Section 16
of the Exchange Act.  The undersigned acknowledges that neither the Company nor
the foregoing attorneys-in-fact assume (i) any liability for the undersigned's
responsibility to comply with the requirement of the Exchange Act, (ii) any
liability of the undersigned for any failure to comply with such requirements,
or (iii) any obligation or liability of the undersigned for profit disgorgement
under Section 16(b) of the Exchange Act.

       This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file Forms 3, 4, and 5 with respect to the
undersigned's holdings of and transactions in securities issued by the Company,
unless earlier revoked by the undersigned in a signed writing delivered to the
foregoing attorneys-in-fact.

       IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of November 1, 2023.



                                              /s/ William C. Fairey
                                              -------------------------
                                              Signature


                                              William C. Fairey
                                              -------------------------
                                              Print Name